A Three-arm, Randomized, Open Label, Phase II Study of Everolimus in Combination With Exemestane Versus Everolimus Alone Versus Capecitabine in the Treatment of Postmenopausal Women With Estrogen Receptor Positive, Locally Advanced, Recurrent, or Metastatic Breast Cancer After Recurrence or Progression on Prior Letrozole or Anastrozole.
Latest Information Update: 07 Nov 2021
At a glance
- Drugs Capecitabine (Primary) ; Everolimus (Primary) ; Exemestane
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Acronyms BOLERO-6
- Sponsors Novartis; Novartis Pharmaceuticals
- 08 Feb 2019 This trial has been completed in the United Kingdom, according to European Clinical Trials Database.
- 20 Aug 2018 Status changed from active, no longer recruiting to completed.
- 11 Jul 2018 Planned End Date changed from 30 Apr 2018 to 30 Jul 2018.